Tetratherix ships first Tetramatrix™ polymer to the US, unlocking product revenue
Tetratherix (ASX:TTX) has dispatched its first commercial shipment of Tetramatrix™ polymer to the United States, marking the start of product revenue generation for its Precision Medicine franchise.
The shipment moves the company’s US partnership beyond a licensing agreement on paper into a genuine supply relationship. It represents the first revenue-generating supply of product under the franchise, which was launched in March 2026.
The polymer is being exported under the exclusive licence and supply agreement announced in March 2026 with Superpower Health, Inc., a US partner developing intranasal delivery products for the consumer and longevity market. The product is branded as STEPP.
When big ASX news breaks, our subscribers know first
Two revenue streams: product supply plus the annual licence fee
The commercial structure is central to the investment case. Product revenue from the polymer supply is in addition to the existing US$3M annual exclusive licence fee, not a replacement for it.
This first shipment consists of validation material, enabling what Tetratherix describes as a “targeted and deliberate trial period” to finalise the operational supply process and begin data collection. In other words, this is an early validation phase rather than mass commercial supply.
The specific product revenue figure has not been disclosed. The table below summarises the two revenue streams.
| Revenue Stream | Description | Status |
|---|---|---|
| Annual licence fee | US$3M exclusive licence fee, recurring | Existing |
| Product supply revenue | Revenue from Tetramatrix™ polymer shipment to US partner | New, trial phase commenced |
The regulatory milestone that opened the export door
The export was made possible by a key regulatory step. In June, the US Food and Drug Administration (FDA) assigned a unique identifier number (UNII) for the Tetramatrix™ platform polymer, branded as STEPP.
According to Tetratherix, this “formalises our Tetramatrix™ proprietary polymer substance registration and enables the export pathway to the US market.” The shipment followed successful completion of the company’s export clearance pathway for the underlying polymer technology.
The sequence of enablers that made the shipment possible can be summarised as follows:
-
FDA UNII assigned (June 2026)
-
Export clearance pathway completed
-
Manufacturing and quality systems scaled from pilot to commercial-grade production
What is Tetramatrix™ and STEPP?
Tetratherix’s broader strategy centres on a single core Tetramatrix™ polymer chemistry. This one chemistry is designed to support multiple medical product derivatives across two areas: regenerative medicine and precision medicine.
Within the regenerative medicine portfolio, the chemistry is simultaneously being validated for advanced wound closure applications, having recently achieved near-healthy skin outcomes in early scar prevention studies.
STEPP is the branded platform polymer used for intranasal delivery, meaning delivery of a drug through the nose rather than by injection or tablet. The company is developing STEPP-based products with its US partner for the consumer and longevity market.
The intranasal focus is commercially relevant because of drugs known as GLP-1 receptor agonists, such as semaglutide.
For investors, the appeal lies in the model itself: one polymer platform supporting multiple revenue-generating product lines, which the company frames as a scalable intellectual property position.
Anchored by science: peer-reviewed validation
The commercial milestone coincided with a scientific validation. A peer-reviewed manuscript detailing the science underpinning the STEPP program has been accepted for publication in the International Journal of Pharmaceutics.
The paper provides independent, peer-reviewed validation of the same core Tetramatrix™ polymer chemistry now being exported to the United States.
Key details of the publication include:
-
Title: “Intranasal delivery of Semaglutide using a thermoresponsive PNPHO nanocarrier: Formulation development, characterization and biological evaluation”
-
Co-authors: Collaborators from Macquarie University, the Woolcock Institute of Medical Research and Aptar Pharma, Inc.
-
Key finding: Tetratherix’s PNPHO polymer can be formulated as a nanocarrier for intranasal semaglutide, achieving enhanced transport across nasal epithelial tissue and prolonged nasal retention in preclinical models
Will Knox, CEO
“This first commercial dispatch of our proprietary polymer is a significant proof point for Tetratherix – it demonstrates that we can take Tetramatrix™ from validated science through to commercial-grade product in the hands of a US partner. It marks the transition of our Precision Medicine franchise from a licensing agreement on paper into a genuine, revenue-generating supply relationship, and reinforces the scalability of our platform across multiple product derivatives.”
Scaling from pilot to a new manufacturing campus
Manufacturing and quality systems have scaled from pilot to commercial-grade production within the company’s current facility, which supported the export of the polymer.
Looking ahead, Tetratherix stated it has paved the path for Tetramatrix™ polymer production to “scale significantly” upon the commissioning of its new TTX advanced manufacturing campus. No timeline for that commissioning was disclosed.
The shipment follows over five years of collaborative research and development in drug delivery across mRNA, proteins, peptides and small molecules, undertaken with multiple research partners including global pharmaceutical leaders and world-leading researchers. This further builds on Tetratherix’s broader strategy of using its single core Tetramatrix™ polymer chemistry to support multiple medical product derivatives.
The scalability of this intellectual property is also being tested in other indications, with the polymer advancing into late-stage clinical trials as a protective hydrogel spacer for radiotherapy patients.
The investment thesis rests on several connected points: a single polymer platform, multiple product derivatives, dual revenue streams combining the recurring licence fee with new product supply, and US market access now formally opened through the FDA UNII registration.
Don’t Miss the Next Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, with in-depth analysis already done. Join 20,000+ subscribers who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.